IGF2BP1 knockdown has been shown to reduce resistance to chemotherapeutic drugs (e.g. 5-fluorouracil, irinotecan, and oxaliplatin) in colorectal cancer (CRC) cells [45]. The gene discussed is IGF2BP1; the disease is colorectal carcinoma.